Biosynthesis and engineering of isoprenoid small molecules

Area of Science:

• Biotechnology
• Metabolic Engineering
• Natural Product Chemistry

Background:

• Isoprenoid secondary metabolites represent a largely untapped reservoir of commercially valuable compounds.
• Current applications include cancer therapy, infectious disease treatment, and crop protection.
• All isoprenoids originate from universal prenyl diphosphate precursors synthesized via two distinct pathways.

Purpose of the Study:

• To explore the potential of isoprenoid secondary metabolites for commercial applications.
• To detail the metabolic engineering strategies for enhancing isoprenoid production in heterologous hosts.
• To review efforts in producing commercial terpenoids like paclitaxel and artemisinin.

Main Methods:

• Metabolic engineering of heterologous hosts to leverage isoprenoid diversity.
• Engineering of the mevalonate pathway to increase universal precursor availability.
• Focus on optimizing biosynthetic pathways for specific isoprenoid production.

Main Results:

• Significant progress has been made in harnessing isoprenoid diversity through metabolic engineering.
• Enhanced mevalonate pathway engineering boosts precursor levels for heterologous production.
• Successful strategies are being developed for the commercial production of key terpenoids.

Conclusions:

• Isoprenoids are a promising class of compounds with broad commercial potential.
• Metabolic engineering and pathway optimization are key to unlocking this potential.
• Continued efforts are focused on the efficient, large-scale production of high-value isoprenoids.